Bristol ups hepatitis C game in $2.5B acquisition
Sunday, January 8, 2012 - 20:30
in Mathematics & Economics
NEW YORK (AP) -- Looking to angle in an a market that is growing fast, Bristol-Myers will spend $2.5 billion to acquire hepatitis C drug developer Inhibitex Inc., which saw its share price double in one day recently on early stage data of a treatment it is developing....